Welcome to Dividends Inside
Welcome to Dividends Inside!

The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.

Drugs Made In America Acquisition Corp.

DMAAR
$0.12 (- $0.01 - 9.39%)
Last updated: Previous Close (2026-05-21)
DMAAR Metrics
Exchange
🇺🇸 NASDAQ XNMS
Nasdaq/NMS (Global Market)United StatesAmerica/New_York
Sector N/A
Industry N/A
ISINN/A
Market Price0.12
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend Frequency N/A
P/E RatioN/A
EPSN/A
Market Cap$2.7M
Book Value-0.22
Price to Book-0.594
Beta0.6
52w High0.14
52w Low0.13
Next Earnings DateN/A
About the Company
Drugs Made In America Acquisition Corp. is a special purpose acquisition company (SPAC) organized to identify and merge with one or more businesses in the pharmaceutical sector. Its primary function is to source acquisition opportunities that can establish a comprehensive, domestically-focused drug manufacturing and distribution platform. The company is particularly focused on advancing U.S.-based pharmaceutical production, aiming to reduce dependence on overseas suppliers by investing in advanced manufacturing technologies and supporting the onshoring of critical supply chains. This approach not only aims to enhance the reliability and cost-efficiency of medication supply but also has implications for national security and job creation within the United States. Under the leadership of a seasoned management and advisory team with deep industry experience, Drugs Made In America Acquisition Corp. positions itself at the intersection of healthcare innovation and industrial policy, seeking to address market and strategic needs within the U.S. pharmaceutical landscape.
Price History
Latest News for DMAAR
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company
NasdaqGM:DMAA 1 Year Share Price vs Fair Value Explore Drugs Made In America Acquisition's Fair Values from the...